Phase I/II Trial of MGCD516 Combined With Nivolumab in Patients With Advanced Clear Cell Renal Cell Cancer That Progressed on Prior VEGF-Targeted Therapy

Trial Profile

Phase I/II Trial of MGCD516 Combined With Nivolumab in Patients With Advanced Clear Cell Renal Cell Cancer That Progressed on Prior VEGF-Targeted Therapy

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 10 Feb 2018

At a glance

  • Drugs Nivolumab (Primary) ; Sitravatinib (Primary)
  • Indications Renal cell carcinoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 10 Feb 2018 At deadline for abstract submission, 4 patients have been treated on this study as per trial design presented at the 2018 Genitourinary Cancers Symposium
    • 10 Feb 2018 Trial design presented at the 2018 Genitourinary Cancers Symposium
    • 24 Apr 2017 Planned End Date changed from 1 Jul 2023 to 1 Apr 2023.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top